Dovramilast is under clinical development by Medicines Development for Global Health and currently in Phase II for Tuberculosis. According to GlobalData, Phase II drugs for Tuberculosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dovramilast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dovramilast overview
Dovramilast (AMG-634) is under development for the treatment of tuberculosis and leprosy type 2 reaction (also known as erythema nodosum leprosum (ENL). The drug candidate is administered orally in form of capsules. It acts by targeting phosphodiesterase 4 (PDE4). It was also under development for discoid lupus erythematosus and subacute cutaneous lupus erythematosus and hemorrhagic fevers such as Junin, Lassa, Ebola, rift valley, immune reconstitution inflammatory syndrome and unspecified indication with new spray dried dispersion formulation
Medicines Development for Global Health overview
Medicines Development for Global Health (MDGH) is a not-for-profit organization. It primarily focuses on the research, development, and delivery of new and improved medicines. The company’s main focus is on diseases that disproportionately affect low- and middle-income countries. MDGH’s product portfolio includes treatments for a range of neglected diseases such as onchocerciasis, scabies, soil-transmitted helminths, lymphatic filariasis, strongyloidiasis, head lice, leprosy type 2 reactions, and tuberculosis. The company’s pipeline products include moxidectin, dovramilast. MDGH is headquartered in Southbank, Victoria, Australia.
For a complete picture of Dovramilast’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
